AstraZeneca liable in post-M&A dispute
The Definiens technology uses biomarkers to track treatment of tumors (Credit: Shutterstock/Jarun Ontakrai)
A tribunal at the German Arbitration Institute (DIS) panel has ordered AstraZeneca to make additional payments under its US$150 million deal to purchase a cancer diagnostics start-up.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now